Ketoconazole

證據等級: L5

預測適應症: 10 個

Ketoconazole: From Fungal Infections to Acne

One-Sentence Summary

Ketoconazole is a broad-spectrum imidazole antifungal agent, originally used to treat systemic and superficial fungal infections including seborrhoeic dermatitis and pityriasis versicolor. The TxGNN model predicts it may be effective for Acne (disease), with 1 active clinical trial and 15 publications currently supporting this direction. The mechanistic basis rests on dual activity: anti-androgenic effects on sebaceous glands and direct inhibitory action against acne-associated microorganisms.

Quick Overview

Item	Content
Original Indication	Antifungal (fungal skin infections, seborrhoeic dermatitis)
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	99.80%
Evidence Level	L3
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Ketoconazole is an imidazole antifungal that primarily acts by inhibiting fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol biosynthesis and disrupting fungal cell membrane integrity. Beyond antifungal action, Ketoconazole also inhibits mammalian steroidogenic enzymes — notably CYP17A1 and CYP11A1 — thereby suppressing androgen synthesis in the adrenal glands and peripheral tissues including sebaceous glands.

This dual mechanism supports the acne repurposing prediction through two independent pathways. First, the anti-androgenic pathway: by suppressing androgen synthesis in sebaceous glands, Ketoconazole can reduce excess sebum production, a central driver of follicular plugging and acne pathogenesis. This is particularly relevant in hormonal acne. Second, the anti-microbial pathway: laboratory studies (PMID 28111792) have shown that Ketoconazole directly inhibits the lipase activity of Cutibacterium acnes (formerly Propionibacterium acnes), the bacterium responsible for acne inflammation. Lipase metabolizes sebum into pro-inflammatory free fatty acids, and its inhibition reduces the inflammatory cascade in acne lesions. Additionally, Ketoconazole effectively suppresses Malassezia folliculitis — a fungal condition that is frequently misdiagnosed as acne vulgaris and often co-presents with it.

The proposed route of administration is topical, which is clinically important. Topical application concentrates the drug's local anti-microbial and anti-inflammatory effects at the site of action while avoiding systemic absorption and the well-documented hepatotoxicity associated with oral Ketoconazole. An ongoing randomized trial (NCT07237763) is directly testing this hypothesis by comparing topical Ketoconazole 2% cream against topical adapalene (a standard first-line retinoid) in mild comedonal and papulopustular acne.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07237763	NA	Active, Not Recruiting	52	Randomized comparison of topical Ketoconazole 2% cream vs topical adapalene 2% cream in mild comedonal and papulopustular acne over 12 weeks; assesses whether Ketoconazole can serve as an alternative to topical retinoids with fewer side effects and better compliance

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33216275	2021	RCT	Pituitary	Phase 3 SONICS trial of levoketoconazole (Ketoconazole enantiomer) in Cushing's syndrome; demonstrated clinically meaningful improvement in signs including acne through cortisol/androgen suppression — supports anti-androgenic mechanism relevant to acne
8090657	1993	Clinical Trial	Polski Tygodnik Lekarski	Anti-androgenic therapy in PCOS-related hyperandrogenism; androgen suppression reduced hirsutism, acne, and seborrhoea within 3 months, supporting Ketoconazole's anti-androgenic mechanism in acne pathogenesis
28111792	2017	Laboratory	Microbiology and Immunology	Ketoconazole directly inhibits C. acnes lipase activity and bacterial growth; lipase drives sebum-derived free fatty acid production that triggers follicular inflammation — provides direct mechanistic evidence for anti-acne activity
20045949	2010	In vitro	Biological & Pharmaceutical Bulletin	Azole antifungals including Ketoconazole demonstrate activity against P. acnes isolates; relevant as antibiotic-resistant C. acnes strains increase globally, creating a need for alternative agents
12566804	2003	Review	Dermatology (Basel)	Comprehensive review of systemic acne treatments; discusses anti-androgenic agents and the growing problem of antibiotic resistance driving interest in novel treatment approaches
32872149	2020	Review	Pharmaceuticals (Basel)	Review of adapalene (the comparator in NCT07237763) therapeutic potential in acne; useful for interpreting the active trial's endpoint and comparator selection
8593718	1995	Clinical Study	Clinical and Experimental Dermatology	Pityrosporum folliculitis frequently misdiagnosed as acne vulgaris; Ketoconazole treatment (oral and topical) was effective — highlights clinical overlap and therapeutic relevance
8255067	1993	Review	Keio Journal of Medicine	Pityrosporum ovale (Malassezia) as opportunistic pathogen in folliculitis and seborrhoeic dermatitis; Ketoconazole is an established effective treatment, supporting its role in acne-Malassezia overlap presentations
19445767	2009	Review/Cohort	BMJ Clinical Evidence	PCOS review: condition associated with hirsutism, acne, and androgen excess in up to 10% of women; provides epidemiological context for the anti-androgenic acne mechanism
39622522	2024	Observational	Southern Medical Journal	Dermatologic formulary optimization at a free clinic; documents real-world prescribing patterns including Ketoconazole in dermatological conditions overlapping with acne management

Singapore Market Information

Ketoconazole is currently not registered in Singapore. No marketing authorizations are on record (total licenses: 0). Any clinical application would require a new regulatory submission or a compassionate use / clinical trial framework.

Safety Considerations

Please refer to the package insert for safety information.

Important: Package insert warnings, contraindications, and drug-drug interaction data were identified as Blocking data gaps in this Evidence Pack and could not be evaluated. Specifically, TFDA package insert warnings (DG001, severity: Blocking) and mechanism of action data (DG002, severity: High) are outstanding. Safety screening (Stage S1) cannot be formally completed until these gaps are resolved.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the dual anti-androgenic and anti-microbial mechanism provides a biologically plausible basis for Ketoconazole in acne treatment, the current evidence sits at Level L3 (one exploratory Phase NA trial and primarily observational/in vitro literature), critical safety data is unresolved at a Blocking severity level, and Ketoconazole has no existing registration in Singapore — together, these factors preclude advancement until key evidence and safety gaps are addressed.

To proceed, the following is needed:

Results from NCT07237763: Completion and publication of the topical Ketoconazole 2% vs adapalene 2% RCT — this would elevate evidence to L2 and provide the first direct clinical efficacy and safety data for topical use in acne
Safety data resolution: Retrieve and review package insert warnings and contraindications (TFDA or equivalent authority); clarify the hepatotoxicity risk profile specifically for topical formulations
Drug interaction assessment: Complete DDI screening, particularly for topical absorption and any systemic CYP enzyme interactions
Regulatory precedent review: Identify whether any regulatory authority has approved topical Ketoconazole for an acne indication, which would support a Singapore regulatory pathway
Comparative effectiveness review: Formal comparison of Ketoconazole against established first-line acne treatments (benzoyl peroxide, topical retinoids, antibiotics) in terms of efficacy, safety, and resistance risk
Mechanism of action documentation: Obtain full DrugBank MOA data (DG002) to support mechanistic analysis in a formal repurposing submission
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.